Pfizer has announced a recall of the anti-smoking treatment Chantix due to the presence of unacceptably high levels of N-nitroso-varenicline, a substance whose long-term use has been linked to a higher risk of cancer.
The drugmaker said on Sept. 16 that it is voluntarily recalling all lots of 0.5 mg and 1 mg Chantix tablets distributed in the United States, U.S. Virgin Islands, and Puerto Rico from May 2019 to September 2021.
